These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 29915428)

  • 1. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors.
    Alvarez MJ; Subramaniam PS; Tang LH; Grunn A; Aburi M; Rieckhof G; Komissarova EV; Hagan EA; Bodei L; Clemons PA; Dela Cruz FS; Dhall D; Diolaiti D; Fraker DA; Ghavami A; Kaemmerer D; Karan C; Kidd M; Kim KM; Kim HC; Kunju LP; Langel Ü; Li Z; Lee J; Li H; LiVolsi V; Pfragner R; Rainey AR; Realubit RB; Remotti H; Regberg J; Roses R; Rustgi A; Sepulveda AR; Serra S; Shi C; Yuan X; Barberis M; Bergamaschi R; Chinnaiyan AM; Detre T; Ezzat S; Frilling A; Hommann M; Jaeger D; Kim MK; Knudsen BS; Kung AL; Leahy E; Metz DC; Milsom JW; Park YS; Reidy-Lagunes D; Schreiber S; Washington K; Wiedenmann B; Modlin I; Califano A
    Nat Genet; 2018 Jul; 50(7):979-989. PubMed ID: 29915428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors.
    Jamison JK; Zhou M; Gelmann EP; Luk L; Bates SE; Califano A; Fojo T
    Oncologist; 2024 Sep; 29(9):817-e1213. PubMed ID: 38886159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
    Gao F; Zafar MI; Jüttner S; Höcker M; Wiedenmann B
    Med Sci Monit; 2018 Nov; 24():8125-8140. PubMed ID: 30420588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract.
    Vicentini C; Fassan M; D'Angelo E; Corbo V; Silvestris N; Nuovo GJ; Scarpa A
    Molecules; 2014 Feb; 19(2):2458-68. PubMed ID: 24566314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
    Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
    Zanini S; Renzi S; Giovinazzo F; Bermano G
    Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: insights from the 2017 ASCO Gastrointestinal Cancers Symposium.
    Iyer R; Phan AT; Boudreaux JP
    Clin Adv Hematol Oncol; 2017 Apr; 15 Suppl 4(4):1-24. PubMed ID: 28654022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.
    Hofving T; Arvidsson Y; Almobarak B; Inge L; Pfragner R; Persson M; Stenman G; Kristiansson E; Johanson V; Nilsson O
    Endocr Relat Cancer; 2018 Mar; 25(3):367-380. PubMed ID: 29444910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signaling networks and the feasibility of computational analysis in gastroenteropancreatic neuroendocrine tumors.
    Chen P; Wang Q; Xie J; Kwok HF
    Semin Cancer Biol; 2019 Oct; 58():80-89. PubMed ID: 31054326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options.
    Strosberg JR
    Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors.
    Hoffman SE; Dowrey TW; Villacorta Martin C; Bi K; Titchen B; Johri S; DelloStritto L; Patel M; Mackichan C; Inga S; Chen J; Grimaldi G; Napolitano S; Wakiro I; Wu J; Yeung J; Rotem A; Sicinska E; Shannon E; Clancy T; Wang J; Denning S; Brais L; Besson NR; Pfaff KL; Huang Y; Kao KZ; Rodig S; Hornick JL; Vigneau S; Park J; Kulke MH; Chan J; Van Allen EM; Murphy GJ
    Sci Adv; 2023 Sep; 9(39):eadd9668. PubMed ID: 37756410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Saif MW
    Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.
    Dijkstra KK; van den Berg JG; Weeber F; van de Haar J; Velds A; Kaing S; Peters DDGC; Eskens FALM; de Groot DA; Tesselaar MET; Voest EE
    Front Endocrinol (Lausanne); 2021; 12():627819. PubMed ID: 33776923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-MET inhibition: novel treatment for sporadic and MEN1-associated GEP NETs.
    Lee ME; Tepede AA; Mandl A; Weinstein LS; Del Rivero J; Agarwal SK; Blau JE
    J Mol Endocrinol; 2020 Aug; 65(2):R1-R17. PubMed ID: 32384260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions.
    Detjen K; Hammerich L; Özdirik B; Demir M; Wiedenmann B; Tacke F; Jann H; Roderburg C
    Neuroendocrinology; 2021; 111(3):217-236. PubMed ID: 32615560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
    Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
    Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets.
    Andersson E; Arvidsson Y; Swärd C; Hofving T; Wängberg B; Kristiansson E; Nilsson O
    Mod Pathol; 2016 Jun; 29(6):616-29. PubMed ID: 26965582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.